What Are The Best Pre- And Post-Procedure Protocols For Fractional Laser To Prevent Pih And Scarring? Key Strategies For Clinics

Aesthetic clinics should use a risk-stratified, peri-procedural protocol—not a one-size-fits-all checklist—for fractional laser resurfacing. The essential elements are careful screening, documented skin preparation, conservative device settings, targeted infection prophylaxis, strict photoprotection, and structured follow-up. These measures reduce excessive inflammation, PIH, infection, delayed healing, and the risk of scarring.

Core takeaway: PIH and scarring are usually reduced by controlling the total inflammatory and thermal burden while protecting the healing barrier. Clinics should identify high-risk patients, test conservative parameters, avoid treating unstable or recently tanned skin, and provide written aftercare with early review.

Build a Risk-Based Pre-Procedure Assessment

Document skin type and pigmentary risk

Record the patient’s Fitzpatrick phototype, recent tanning or sun exposure, history of PIH, melasma, keloids, hypertrophic scars, and prior reactions to lasers or peels.

Patients with darker phototypes, active tanning, melasma, or a personal history of dyschromia require more conservative treatment planning and closer follow-up. A recent tan should generally be treated as a reason to postpone treatment.

Assess barrier integrity and active disease

Do not treat skin with active dermatitis, significant irritation, sunburn, open wounds, uncontrolled acne inflammation, or active bacterial, fungal, or viral infection.

Evaluate whether the patient has recently undergone a peel, aggressive exfoliation, waxing, or another energy-based procedure. Treatment should be deferred until the epidermal barrier has recovered.

Review medications and healing risks

Document isotretinoin exposure, immunosuppressive therapy, photosensitizing drugs, anticoagulants, antiplatelet drugs, and medical conditions that may impair healing.

Do not instruct patients to stop aspirin, anticoagulants, NSAIDs, or prescribed medication without clearance from the prescribing clinician. These drugs may affect bruising or procedural planning, but stopping them can create serious medical risk.

Discuss scarring and realistic outcomes

Obtain informed consent covering expected erythema, edema, crusting, temporary darkening, acne or milia, infection, PIH, hypopigmentation, prolonged redness, and rare hypertrophic or atrophic scarring.

Patients with a history of abnormal scarring may need specialist assessment before treatment. The clinic should also explain that more aggressive settings do not automatically produce better outcomes.

Prepare the Skin Before Laser Delivery

Enforce sun and tanning avoidance

Require strict avoidance of tanning beds and unnecessary sun exposure for at least 2–4 weeks before treatment, with longer avoidance when the patient remains visibly tanned or has active pigmentary instability.

Use a broad-spectrum sunscreen, preferably with strong UVA and visible-light protection. Tinted mineral formulations containing iron oxides may be useful for patients prone to melasma or visible-light-induced pigmentation.

Use pigment suppression selectively

For patients with darker phototypes or a history of PIH, clinicians may consider a pre-treatment course of a tyrosinase-inhibiting or depigmenting agent, such as hydroquinone, azelaic acid, or another appropriate prescription regimen.

Hydroquinone is not suitable for every patient and can itself cause irritation or, rarely, ochronosis with inappropriate prolonged use. The regimen should be selected and supervised by a qualified clinician rather than applied automatically to every patient.

Pause irritating topical products

Suspend topical retinoids, strong exfoliating acids, and superficial chemical peels before treatment. The exact interval should reflect the product, treatment depth, and the patient’s barrier condition; several days may be sufficient for superficial procedures, whereas approximately 1–2 weeks is commonly used for more aggressive fractional treatments.

Treatment should be postponed if the patient remains visibly irritated, peeling, or inflamed.

Clarify isotretinoin management

A blanket rule requiring six or twelve months of isotretinoin discontinuation is not supported uniformly by modern evidence for every laser procedure. The decision should be individualized according to the drug, dose, timing, treatment type, skin condition, and the treating physician’s judgment.

For aggressive ablative resurfacing or patients with additional healing risks, obtain appropriate dermatologic or medical clearance rather than relying on a fixed interval alone.

Provide antiviral prophylaxis when indicated

Patients with a history of herpes simplex involving the treatment area—especially those undergoing ablative resurfacing—should receive clinician-directed antiviral prophylaxis beginning before or at the time of treatment and continuing through the period of highest risk.

Routine antibiotics or antifungals are not indicated for every patient. They should be reserved for specific clinical indications, documented infection risks, or local protocols.

Control the Laser-Related Inflammatory Burden

Select conservative parameters

Use the lowest effective fluence, pulse energy, density, and treatment coverage that can reasonably achieve the clinical goal.

High energy, excessive density, repeated passes, and overlapping pulses increase thermal injury and inflammation. These factors can raise the risk of PIH, delayed healing, infection, and scarring.

Match settings to skin type and treatment area

Darker phototypes generally require greater caution with energy, density, and treatment depth. Thin skin, mobile areas, previously treated skin, and areas with active inflammation may require further reduction in treatment intensity.

The operator should follow the device manufacturer’s safety guidance and use settings supported by clinical experience for the specific device, wavelength, and indication.

Use test spots for higher-risk cases

Perform a test patch when treating darker phototypes, recently pigment-prone skin, unfamiliar devices, new treatment settings, or patients with a history of adverse pigmentary responses.

Assess the test area after an appropriate interval before proceeding to a larger treatment area. A test spot does not eliminate risk, but it can reveal an excessive inflammatory or pigmentary response.

Prevent unnecessary thermal accumulation

Avoid excessive overlap and monitor the cumulative effect of multiple passes. Use appropriate cooling when supported by the device and treatment protocol, while recognizing that cooling does not compensate for overly aggressive energy settings.

The objective is controlled microscopic injury with sufficient surrounding intact tissue to support rapid re-epithelialization.

Establish Immediate Post-Procedure Care

Protect and restore the skin barrier

Immediately after treatment, use a gentle cleanser, bland emollient, and a non-irritating wound-care regimen appropriate to whether the procedure was nonablative or ablative.

Patients should not pick, scrub, exfoliate, or remove crusts manually. Mechanical trauma can prolong inflammation and increase both PIH and scarring risk.

Apply strict photoprotection

Once tolerated and appropriate for the treatment depth, use a broad-spectrum sunscreen and physical protection such as hats and shade.

Sun and visible-light exposure during healing can amplify melanogenesis. Photoprotection should continue rigorously for several weeks, and longer for patients with darker phototypes or a history of PIH.

Delay irritating actives

Retinoids, exfoliating acids, benzoyl peroxide, fragranced products, and depigmenting agents should generally remain suspended until the barrier has adequately recovered.

Depigmenting therapy may often be restarted after approximately 1–2 weeks for uncomplicated recovery, or later after more aggressive ablative treatment. The correct timing is based on re-epithelialization, absence of significant irritation, and clinician assessment.

Treat emerging PIH early

At the first sign of persistent or worsening post-treatment darkening, assess the patient rather than waiting for the pigment to resolve spontaneously.

A clinician may restart or prescribe a pigment-suppressing regimen, but treatment should not be applied to raw, eroded, or actively inflamed skin.

Monitor for Infection and Abnormal Healing

Give patients specific warning signs

Written instructions should identify symptoms requiring prompt contact, including increasing rather than improving pain, spreading redness, purulent drainage, fever, grouped vesicles, worsening swelling, or delayed re-epithelialization.

Early treatment of infection is important because infection can intensify inflammation and contribute to PIH or scarring.

Schedule structured follow-up

Follow-up should be based on treatment depth and risk, with earlier review for ablative procedures, darker phototypes, test-spot abnormalities, or patients with prior complications.

Document healing, erythema, crusting, pigment changes, infection signs, and any evidence of hypertrophic scarring. Escalate persistent inflammation, delayed healing, or suspected scarring to a dermatologist or other appropriately qualified clinician.

Understanding the Trade-offs

More aggressive treatment increases risk

Higher fluence and density may produce a stronger resurfacing effect, but they also increase thermal injury, downtime, PIH, infection, and scarring risk.

For patients at high pigmentary risk, a staged course of conservative treatments is often safer than one aggressive session.

Pretreatment can also irritate skin

Retinoids, hydroquinone, acids, and other active products may improve pigment control when tolerated, but irritation before laser treatment can increase inflammation and make PIH more likely.

The correct protocol is not the most intensive regimen; it is the regimen that leaves the skin calm and intact at the time of treatment.

Medication rules must be individualized

Fixed discontinuation periods for isotretinoin or routine cessation of blood thinners can oversimplify clinical decision-making and create avoidable harm.

Medication changes should be coordinated with the prescribing clinician and documented in the treatment record.

“Fractional” does not mean risk-free

Fractional delivery leaves untreated skin between microscopic treatment columns, which generally supports faster healing than fully confluent resurfacing. However, excessive depth, density, heat, overlap, or poor aftercare can still produce significant PIH, infection, and scarring.

How to Apply This to Your Clinic

A practical clinic protocol should combine standardized documentation with individualized treatment decisions:

If your primary focus is PIH prevention: Screen for phototype, tanning, melasma, prior PIH, and barrier damage; use conservative settings, appropriate pigment suppression, test patches, and strict UV and visible-light protection.
If your primary focus is scarring prevention: Avoid treating inflamed or infected skin, limit energy and overlap, protect the barrier, prevent picking, and review any delayed healing or persistent inflammation early.
If your primary focus is infection prevention: Identify herpes simplex risk, provide targeted antiviral prophylaxis when indicated, maintain clean technique, and give clear instructions for recognizing infection.
If your primary focus is operational consistency: Use a written checklist covering medications, contraindications, test spots, device parameters, consent, aftercare, and scheduled follow-up.
If your primary focus is treating darker phototypes: Favor staged, conservative treatments and require a documented pigment-management and photoprotection plan rather than applying standard settings automatically.

The safest fractional laser protocol is one that controls inflammation before, during, and after treatment while adapting every decision to the patient’s skin, medical history, and healing response.

Summary Table:

Phase	Key Action	Purpose
Pre-procedure	Assess Fitzpatrick skin type, history of PIH, and barrier integrity.	Identify high-risk patients and tailor treatment.
Pre-procedure	Enforce sun avoidance and use broad-spectrum sunscreen.	Reduce melanocyte stimulation and PIH risk.
Pre-procedure	Consider pigment suppression (e.g., hydroquinone) for high-risk patients.	Stabilize melanocytes before injury.
Intra-procedure	Use conservative fluence and density settings.	Limit thermal damage and inflammation.
Intra-procedure	Perform test spots for high-risk cases.	Evaluate individual response before full treatment.
Post-procedure	Protect barrier with gentle cleanser and emollients.	Promote re-epithelialization and reduce irritation.
Post-procedure	Strict photoprotection for weeks.	Prevent UV-induced pigmentation.
Post-procedure	Delay actives (retinoids, acids) until healed.	Avoid irritation during critical healing.
Post-procedure	Early intervention for PIH signs.	Minimize pigment persistence.
Follow-up	Schedule structured follow-up based on risk.	Detect and manage complications early.

Ready to elevate your clinic's laser safety and efficacy? At BELIS, we provide advanced aesthetic devices and clinical training to help you achieve optimal results. Our portfolio includes fractional lasers (CO2, Erbium) designed for safe, effective resurfacing. We support clinics and premium salons with OEM/ODM services, certifications, and reliable supply. Contact our experts today to discuss how our technology and protocols can enhance your practice—contact us for a personalized consultation.